Clinical Trials Browser

Completed × Triple Negative Breast Neoplasms × Epirubicin × Clear all

NCT04877821 2026-04-02

NeoSACT

Phase 2 Completed

Triple Negative Breast Neoplasms

NCT03036488 2025-10-29

MK-3475-522

Phase 3 Completed

1,174 enrolled 1 FDA

Triple Negative Breast Neoplasms

NCT03356860 2024-11-20

B-IMMUNE

Phase 1/2 Completed

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03289819 2021-04-08

NIB

Phase 2 Completed

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02789332 2020-03-17

GeparOla

Phase 2 Completed

Kenny-Caffey syndrome, Type 1, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01624441 2018-03-30

Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer

Phase 1 Completed

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms